

Supplemental Figure 2. Kaplan Meier curves for progression-free survival (panel A) and overall survival (panel B) in dMMR/MSI-H mCRC patients according to the type of peritoneal involvement (no peritoneal metastases vs peritoneal metastases and no ascites vs peritoneal metastases and ascites) and to the type of ICI regimens (anti-PD(L)-1 monotherapy vs dual anti-CTLA-4/PD1 combination).

